Zentalis Pharmaceuticals Files Proxy Statement Amendment
Ticker: ZNTL · Form: DEFA14A · Filed: May 23, 2025 · CIK: 1725160
Sentiment: neutral
Topics: proxy-statement, amendment, sec-filing
TL;DR
Zentalis filed an amendment to its proxy statement, shareholders need to review for meeting updates.
AI Summary
Zentalis Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement (DEFA14A) on May 23, 2025. This filing concerns the company's proxy materials, indicating updates or additional information related to a shareholder meeting. The company, headquartered in San Diego, CA, operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides updated information to shareholders regarding company matters, which is crucial for informed voting decisions at upcoming shareholder meetings.
Risk Assessment
Risk Level: low — This is a routine administrative filing related to proxy statements, not indicating significant new risks or events.
Key Players & Entities
- Zentalis Pharmaceuticals, Inc. (company) — Registrant
- 0001725160-25-000112 (filing_id) — Accession Number
- 20250523 (date) — Filing Date
- San Diego, CA (location) — Company Headquarters
FAQ
What type of filing is this DEFA14A amendment?
This is an amendment (Amendment No. 1) to a Definitive Proxy Statement (DEFA14A) filed by Zentalis Pharmaceuticals, Inc.
When was this amendment filed?
The amendment was filed on May 23, 2025.
What is the primary business of Zentalis Pharmaceuticals, Inc.?
Zentalis Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
Where is Zentalis Pharmaceuticals, Inc. located?
The company's business and mailing address is 10275 Science Center Drive, Suite 200, San Diego, CA 92121.
What is the purpose of a DEFA14A filing?
A DEFA14A filing is a Definitive Proxy Statement, used to solicit proxies from shareholders for an upcoming meeting, and this filing is an amendment to that statement.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 23, 2025 regarding Zentalis Pharmaceuticals, Inc. (ZNTL).